Novo Nordisk looks at ways to raise diabetes awareness in new report
PRINCETON, N.J. Novo Nordisk is underscoring the importance of diabetes screenings with a new report, the Novo Nordisk BlueSheet.
The third edition of the drug maker’s BlueSheet report examined various ways awareness and education play an integral role in the prevention, detection and treatment of diabetes. It also provides an update on the Diabetes Advocacy Alliance, a coalition that is committed to helping improve diabetes prevention, detection and care by aligning key diabetes stakeholders around diabetes-related policy and legislative efforts.
"Living with a chronic disease like diabetes is a challenge, which is why education and intervention are such important factors in successful long-term outcomes for patients," said Jerzy Gruhn, president of Novo Nordisk. "At Novo Nordisk, we understand that coping with diabetes requires knowledge, skill and support. That is why we remain committed to the education of patients and healthcare professionals. We believe it is one of the most powerful tools we have in the fight against diabetes today."
Teva, Sandoz launch Prevacid SoluTab generics
JERUSALEM The Food and Drug Administration granted approval for Teva’s abbreviated new drug application to market a generic version of a drug designed to treat peptic ulcers.
The generic drug maker said that its drug, lansoprazole, is a generic version of Takeda’s Prevacid SoluTab. Annual sales of the branded product were approximately $453 million in the United States, according to IMS sales data.
Sandoz, the generics division of Swiss drug maker Novartis, also announced the launch of its own version of Prevacid SoluTab.
FDA OKs expanded use of Baraclude
PRINCETON, N.J. The Food and Drug Administration has approved an additional use for a hepatitis drug.
Bristol-Myers Squibb announced Monday the approval of Baraclude (entecavir) as a treatment for chronic hepatitis B in adults with decompensated liver disease. The drug already is approved for adults with evidence of active viral replication.
“This additional indication for Baraclude is important news as it is now proven to be an effective treatment option for physicians to help in managing chronic hepatitis B patients with decompensated liver disease,” University of Hawaii professor of medicine Naoky Tsai said.